HK1008774A1 - A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof - Google Patents

A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof

Info

Publication number
HK1008774A1
HK1008774A1 HK98109537A HK98109537A HK1008774A1 HK 1008774 A1 HK1008774 A1 HK 1008774A1 HK 98109537 A HK98109537 A HK 98109537A HK 98109537 A HK98109537 A HK 98109537A HK 1008774 A1 HK1008774 A1 HK 1008774A1
Authority
HK
Hong Kong
Prior art keywords
glass
active agent
composition
pct
preparation
Prior art date
Application number
HK98109537A
Other languages
English (en)
Inventor
Ake Lindahl
Original Assignee
Bioglan Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioglan Ab filed Critical Bioglan Ab
Publication of HK1008774A1 publication Critical patent/HK1008774A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
HK98109537A 1995-06-20 1998-07-29 A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof HK1008774A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9502244A SE9502244D0 (sv) 1995-06-20 1995-06-20 A composition and a process for the preparation thereof
PCT/SE1996/000806 WO1997000670A1 (en) 1995-06-20 1996-06-19 A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof

Publications (1)

Publication Number Publication Date
HK1008774A1 true HK1008774A1 (en) 1999-05-21

Family

ID=20398685

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98109537A HK1008774A1 (en) 1995-06-20 1998-07-29 A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof

Country Status (15)

Country Link
US (1) US6083518A (de)
EP (1) EP0833611B1 (de)
JP (1) JP4020331B2 (de)
AT (1) ATE204466T1 (de)
AU (1) AU695622B2 (de)
CA (1) CA2225286C (de)
DE (2) DE833611T1 (de)
DK (1) DK0833611T3 (de)
ES (1) ES2118677T3 (de)
HK (1) HK1008774A1 (de)
NZ (1) NZ311208A (de)
PT (1) PT833611E (de)
SE (1) SE9502244D0 (de)
WO (1) WO1997000670A1 (de)
ZA (1) ZA965237B (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136814A (en) * 1997-12-08 2000-10-24 Fujisawa Usa, Inc. Aqueous acyclovir product
SE9801704D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
SE9801705D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
EP1216037A2 (de) * 1999-09-21 2002-06-26 Emory University Verfahren und zusammensetzungen zur behandlung von bluttplätchen-zusammenhängenden krankheiten, mit mpl hemmenden agenten
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
JP4512700B2 (ja) * 2003-06-02 2010-07-28 トーアエイヨー株式会社 アシクロビル含有水溶液製剤
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
JP4896006B2 (ja) 2004-04-08 2012-03-14 バイオマトリカ, インコーポレイテッド ライフサイエンスのためのサンプル保存とサンプル管理との統合
EA017290B1 (ru) 2005-11-28 2012-11-30 Домейн Раша Инвестментс Лимитед Композиции на основе ганаксолона
GB2432528B (en) * 2005-11-29 2011-04-06 Ian Ripley Anti-viral compositions comprising flavanone glycosides and fruit acids
WO2007102243A1 (ja) 2006-03-08 2007-09-13 Nihon Nohyaku Co., Ltd. 外用の医薬組成物
US8349882B2 (en) * 2006-03-08 2013-01-08 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
RU2419429C2 (ru) * 2006-03-08 2011-05-27 Нихон Нохияку Ко.,Лтд. Фармацевтическая композиция для наружного применения
AU2007260739A1 (en) * 2006-06-14 2007-12-21 Dr. Reddy's Laboratories Limited Topical compositions
EP2081435B1 (de) 2006-09-22 2016-05-04 Pharmacyclics LLC Hämmer der bruton-tyrosinkinase
KR100721126B1 (ko) 2006-12-28 2007-05-23 (주)바이오앤에이치엔티 모기 기피제 조성물
CN101808637B (zh) * 2007-09-05 2013-07-24 宝丽制药股份有限公司 医药组合物
JP5453093B2 (ja) * 2007-09-05 2014-03-26 株式会社ポーラファルマ 抗真菌医薬組成物
JP5345937B2 (ja) * 2007-09-05 2013-11-20 株式会社ポーラファルマ 抗真菌組成物
CA2699157A1 (en) 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP5421901B2 (ja) 2008-03-31 2014-02-19 国立大学法人広島大学 エンテロウイルス属の非エンベロープウイルスに対する抗ウイルス剤および抗ウイルス用組成物
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
MX2011002149A (es) 2008-08-27 2011-04-05 Calcimedica Inc Compuestos que modulan el calcio intracelular.
EP2385821B1 (de) * 2009-01-09 2016-08-31 Egis Gyógyszergyár Zrt. Verbesserte pharmazeutische formulierung
EP2745692A1 (de) * 2009-02-13 2014-06-25 Topica Pharmaceuticals, Inc Luliconazole-enthaltende antimykotische Formulierung
US10130610B2 (en) 2009-04-09 2018-11-20 Pola Pharma Inc. Antimycotic pharmaceutical composition
EP2416758B8 (de) 2009-04-09 2017-10-18 Pola Pharma Inc. Antimykotische pharmazeutische zusammensetzung
CN102481286B (zh) 2009-08-25 2014-02-26 宝丽制药股份有限公司 抗真菌药物组合物
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EP2558866B1 (de) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potenzierung einer antikrebs-wirkung durch eine kombinationstherapie mit ber-pfad-hemmern
WO2011139489A2 (en) 2010-04-27 2011-11-10 Calcimedica Inc. Compounds that modulate intracellular calcium
AU2011248579A1 (en) 2010-04-27 2012-11-29 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
US9845489B2 (en) 2010-07-26 2017-12-19 Biomatrica, Inc. Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US9079891B2 (en) 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2014100755A2 (en) 2012-12-20 2014-06-26 Biomatrica, Inc. Formulations and methods for stabilizing pcr reagents
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015084998A1 (en) 2013-12-05 2015-06-11 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20150224078A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the Treatment of Lung Diseases with Mast Cell Stabilizers
SI3104853T1 (sl) 2014-02-10 2020-03-31 Respivant Sciences Gmbh Zdravljenje s stabilizatorji mastocitov za sistemske motnje
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
ES2786373T3 (es) 2014-06-10 2020-10-09 Biomatrica Inc Estabilización de trombocitos a temperaturas ambiente
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
JP2018510138A (ja) 2015-02-27 2018-04-12 カーテナ ファーマシューティカルズ,インク. Olig2活性の阻害
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
ES2946184T3 (es) 2015-12-08 2023-07-13 Biomatrica Inc Reducción de la velocidad de eritrosedimentación
WO2017147146A1 (en) 2016-02-23 2017-08-31 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
ES2910787T3 (es) 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
US10821105B2 (en) 2016-05-25 2020-11-03 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
JP7028860B2 (ja) 2016-08-26 2022-03-02 カーテナ ファーマシューティカルズ,インク. Olig2活性の阻害
CA3035528A1 (en) 2016-08-31 2018-03-08 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
EP3522983A4 (de) 2016-10-07 2020-06-03 Respivant Sciences GmbH Cromolynzusammensetzung zur behandlung von lungenfibrose
WO2019094434A1 (en) 2017-11-07 2019-05-16 The Regents Of The University Of Michigan Therapeutic combination for treatment of cerebellar ataxia
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
CN112040947A (zh) 2017-12-07 2020-12-04 密歇根大学董事会 Nsd家族抑制剂及用其进行治疗的方法
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
US11319302B2 (en) 2018-06-07 2022-05-03 The Regents Of The University Of Michigan PRC1 inhibitors and methods of treatment therewith
WO2020023794A1 (en) 2018-07-27 2020-01-30 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic trpv1 agonists
GB2591681A (en) 2018-08-29 2021-08-04 Ftf Pharma Private Ltd Methotrexate pharmaceutical composition
US20200069742A1 (en) 2018-08-29 2020-03-05 Myos Rens Technology Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
US20200108102A1 (en) 2018-10-03 2020-04-09 Myos Rens Technology Inc. Spray dried follistatin product
WO2020085904A2 (en) 2018-10-24 2020-04-30 SeraNovo B.V. Deep eutectic solvent platform for oral pharmaceutical formulations
NL2021864B1 (en) * 2018-10-24 2020-05-13 Seranovo B V Deep Eutectic Solvent Platform for Oral Pharmaceutical Formulations
WO2020096660A1 (en) 2018-11-06 2020-05-14 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
MX2021007925A (es) 2018-12-31 2021-10-26 Biomea Fusion Llc Inhibidores irreversibles de la interaccion menina-mll.
US11833186B2 (en) 2019-02-01 2023-12-05 Myos Corp. Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals
WO2020190890A1 (en) 2019-03-15 2020-09-24 Unicycive Therapeutics Inc. Nicorandil derivatives
CN116113406A (zh) 2020-07-10 2023-05-12 密歇根大学董事会 Gas41抑制剂及其使用方法
CA3202151A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
WO2023018825A1 (en) 2021-08-11 2023-02-16 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
US11945785B2 (en) 2021-12-30 2024-04-02 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of FLT3
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US33221A (en) * 1861-09-03 Improvement in soap
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
USRE33221E (en) 1982-04-29 1990-05-22 American Dental Association Health Foundation Dental restorative cement pastes
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
EP0319988A1 (de) * 1987-12-09 1989-06-14 Showa Denko Kabushiki Kaisha Aüsserliche dermatologische Zubereitung
US5215757A (en) * 1991-03-22 1993-06-01 The Procter & Gamble Company Encapsulated materials
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
DK0617612T3 (da) * 1991-12-18 1998-04-14 Warner Lambert Co Fremgangsmåde til fremstilling af en fast dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine

Also Published As

Publication number Publication date
AU695622B2 (en) 1998-08-20
JPH11508250A (ja) 1999-07-21
AU6247396A (en) 1997-01-22
NZ311208A (en) 1999-03-29
DE833611T1 (de) 1999-01-07
CA2225286A1 (en) 1997-01-09
US6083518A (en) 2000-07-04
DK0833611T3 (da) 2001-10-08
SE9502244D0 (sv) 1995-06-20
ATE204466T1 (de) 2001-09-15
DE69614689D1 (de) 2001-09-27
ES2118677T3 (es) 2001-10-16
JP4020331B2 (ja) 2007-12-12
EP0833611A1 (de) 1998-04-08
DE69614689T2 (de) 2002-06-27
ES2118677T1 (es) 1998-10-01
CA2225286C (en) 2003-06-10
EP0833611B1 (de) 2001-08-22
PT833611E (pt) 2002-01-30
ZA965237B (en) 1997-01-09
WO1997000670A1 (en) 1997-01-09

Similar Documents

Publication Publication Date Title
ZA965237B (en) A composition and a process for the preparation thereof
HU76547A2 (en) Process for producing pharmaceutical compositions containing agent in polymer-matrix and in solid solution form and these medicaments
FI103091B1 (fi) Menetelmä viivästyneesti vapauttavan koostumuksen valmistamiseksi
MY121192A (en) New compounds.
NO971965D0 (no) Farmasöytisk preparat inneholdende en smeltbar bærer og fremgangsmåte for fremstilling derav
IL115920A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING omega-SUBSTITUTED 2,2-DICHLOROALKANECARBOXYLIC ACIDS, SOME SUCH NEW COMPOUNDS AND PROCESS FOR THEIR PREPARATION
IS3966A (is) Aðferð til framleiðslu á lyfjablöndum sem innihalda nifedipine
DE69620866T2 (de) Vehrfahren zur herstellung von beta-lactam antibiotikum enthaltenden oralen dosisformen
HUT72594A (en) New prednisolone derivative, process for its production, pharmaceutical composition containing the same
ATE237316T1 (de) Ibuprofen und domperidone enthaltende pharmazeutische zusammensetzungen
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
EP0305194A3 (de) Tierärztliche Zusammensetzung
JPS57136503A (en) Expellent for noxious mollusk
IL117734A (en) Anellated beta-carbolines their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20050619